ProShare Advisors LLC Sells 1,538,125 Shares of Kenvue Inc. (NYSE:KVUE)

ProShare Advisors LLC lowered its stake in shares of Kenvue Inc. (NYSE:KVUE) by 15.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,433,858 shares of the company’s stock after selling 1,538,125 shares during the quarter. ProShare Advisors LLC owned 0.44% of Kenvue worth $180,063,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of KVUE. Grove Bank & Trust grew its position in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in Kenvue in the 4th quarter valued at $29,000. SRS Capital Advisors Inc. grew its position in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Asset Planning Inc bought a new position in Kenvue in the 4th quarter valued at $42,000. Finally, Clarity Asset Management Inc. bought a new position in Kenvue in the 4th quarter valued at $45,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 1.7%

Shares of NYSE KVUE opened at $23.26 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market capitalization of $44.63 billion, a P/E ratio of 43.89, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17. The business has a fifty day moving average price of $23.15 and a 200 day moving average price of $22.58.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. The firm had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The firm’s quarterly revenue was down 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 EPS. Equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.53%. The ex-dividend date is Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 price target on the stock. Citigroup increased their price target on Kenvue from $22.00 to $24.50 and gave the stock a “neutral” rating in a research report on Friday, May 9th. UBS Group increased their price target on Kenvue from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Friday, May 9th. Barclays increased their price target on Kenvue from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Monday. Finally, Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.